1. NF-κB
    Stem Cell/Wnt
    MAPK/ERK Pathway
    Autophagy
  2. Keap1-Nrf2
    ERK
    Autophagy
  3. TBHQ

TBHQ (Synonyms: tert-Butylhydroquinone)

Cat. No.: HY-100489 Purity: >98.0%
Handling Instructions

TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2. TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma.

For research use only. We do not sell to patients.

TBHQ Chemical Structure

TBHQ Chemical Structure

CAS No. : 1948-33-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 66 In-stock
Estimated Time of Arrival: December 31
1 g USD 60 In-stock
Estimated Time of Arrival: December 31
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 9 publication(s) in Google Scholar

Top Publications Citing Use of Products

    TBHQ purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2018 Jun 7;500(3):790-796.

    Macrophages are isolated from wild-type mice, treated with tBHQ (100 μM) or not, and induced for 3 h using LPS, IFN-g, IL-4 or IL-13. Western blot analysis of the expression of Nrf2, p65 subunit of NF-kB, phosphorylated p65 and PPARg in the cytoplasm and nucleus.

    TBHQ purchased from MCE. Usage Cited in: Front Pharmacol. 2018 Jun 6;9:540.

    BHQ promotes higher protein expression of Nrf2 in a time-dependent manner in neonatal rat cardiac fibroblasts (NRCF) while notably downregulated collagen I and collagen III.

    View All ERK Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2[1]. TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma[2].

    IC50 & Target[1][2]

    Nrf2

     

    ERK

     

    Autophagy

     

    In Vitro

    TBHQ (t-butylhydroquinone; tBHQ; 0-100 μM; 48 hours; H9c2 cells) alone does not affect H9c2 cells viability. Pre-incubation of the H9c2 cells with various concentrations of tBHQ for 24 hours enhances cell viability which is decreased due to exposure to ethanol in a dose-dependent manner. Treatment with tBHQ markedly enhances the viability of H9c2 cardiomyocytes exposed to ethanol[3].
    TBHQ (5 μM; 15 min; H9c2 cells) treatment significantly reduces the amount of apoptotic cells exposed to ethanol[3].
    TBHQ (5 μM; H9c2 cells) pre-treatment markedly inhibites the ethanol-induced increase in caspase-3 and Bax expression, and enhances Bcl-2 expression[3].

    Cell Viability Assay[3]

    Cell Line: H9c2 cells
    Concentration: 0 µM, 0.625 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 20 µM, 50 µM and 100 µM
    Incubation Time: 48 hours
    Result: Enhanced the viability of H9c2 cardiomyocytes exposed to ethanol.

    Apoptosis Analysis[3]

    Cell Line: H9c2 cells
    Concentration: 5 μM
    Incubation Time:
    Result: Lowered the amount of apoptotic cells exposed to ethanol.

    Western Blot Analysis[3]

    Cell Line: H9c2 cells
    Concentration: 5 μM
    Incubation Time:
    Result: Inhibited the ethanol-induced increase in caspase-3 and Bax expression, and enhanced Bcl-2 expression.
    In Vivo

    TBHQ treatment (50 mg/kg; Intraperitoneal injection; three injections at intervals of 8 h that began 1-h post ICH; CD-1 mice) augments the DNA-Binding activity of Nrf2, attenuates oxidative brain damage and acute neurological deficits afterintracerebral hemorrhage (ICH), attenuates microglial activation with concomitant reduction in the release of proinflammatory cytokine interleukin-1β (IL-1β). TBHQ has the efficacy of post-injury administration in attenuating acute neurological injury after ICH[4].

    Animal Model: Male CD-1 mice (8-10 weeks old)[4]
    Dosage: 50 mg/kg
    Administration: Intraperitoneal injection; three injections at intervals of 8 hours that began 1h post ICH.
    Result: The treatment augmented the DNA-binding activity of Nrf2, attenuated brain oxidative damage, attenuated the microglial activation and the expression of IL-1β.
    Molecular Weight

    166.22

    Formula

    C₁₀H₁₄O₂

    CAS No.

    1948-33-0

    SMILES

    OC1=CC=C(O)C=C1C(C)(C)C

    Shipping

    Room temperature in continental US; may vary elsewhere

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 56.66 mg/mL (340.87 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 6.0161 mL 30.0806 mL 60.1612 mL
    5 mM 1.2032 mL 6.0161 mL 12.0322 mL
    10 mM 0.6016 mL 3.0081 mL 6.0161 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (15.04 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    TBHQ
    Cat. No.:
    HY-100489
    Quantity: